SCHEDULE: Soleus Capital Discloses 6.3% Stake in Biodesix
Beneficial Ownership Disclosure
Soleus Capital Master Fund and related entities have reported a 6.3% beneficial ownership stake in Biodesix Inc., totaling 500,000 common shares.
Summary
- Soleus Capital Master Fund, L.P., along with its affiliated entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 500,000 shares of Biodesix Inc. common stock.
- This ownership represents 6.3% of Biodesix Inc.'s outstanding common stock.
- The percentage is calculated based on 7,955,685 shares outstanding as of October 28, 2025, as reported in Biodesix's Form 10-Q for the fiscal quarter ended September 30, 2025.
- The shares are held directly by Soleus Capital Master Fund, L.P.
- All reporting persons share voting and dispositive power over the 500,000 shares.
- The acquisition was not for the purpose of changing or influencing control of Biodesix Inc., except for activities related to a nomination under Rule 14a-11.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of beneficial ownership by an institutional investor. The acquisition of a significant stake (6.3%) by Soleus Capital could be interpreted as a positive signal of institutional confidence in Biodesix Inc., but the filing itself does not contain performance data or forward-looking statements from the issuer.
Positives
- An institutional investor, Soleus Capital Master Fund, L.P., has taken a significant stake (6.3%) in Biodesix Inc., potentially signaling confidence in the company's future.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially the stock price, indicating increased institutional interest or validation.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | End of fiscal quarter for Biodesix Inc.'s Form 10-Q. |
| 2025-10-28 | Date as of which 7,955,685 shares of Biodesix Inc. common stock were outstanding. |
| 2025-11-03 | Date Biodesix Inc. filed its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025. |
| 2026-01-12 | Date of event which required the filing of this Schedule 13G statement. |
| 2026-01-13 | Date of signing and filing of the Schedule 13G statement and Joint Filing Agreement. |
Keywords
Biodesix Inc, Soleus Capital, institutional ownership, beneficial ownership, common stock, SEC filing, Schedule 13G, investment, healthcare, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.